top of page

EC approves Revlimid for mantle cell lymphoma

Celgene’s Revlimid (lenalidomide) has been approved by the European Commission (EC) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page